ShangBay Capital's William Dai Recognized Among GrowthCap's Top 25 Healthcare Investors for 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--ShangBay Capital, a prominent venture capital firm specializing in healthcare investments, proudly announces the inclusion of William Dai in GrowthCap's esteemed list of top healthcare investors for 2025.
This prestigious accolade marks William Dai's third year being recognized as one of GrowthCap's Top 25 Healthcare Investors. His exceptional contributions to the healthcare sector, alongside a distinguished cohort of industry leaders, highlight his position as one of the foremost investors in the field. The selection process focused on investment expertise, track record, impact on the healthcare landscape, and support for portfolio company growth.
William Dai, Founding Managing Partner at ShangBay Capital, spearheads the firm's healthcare investment initiatives, with a particular emphasis on medtech ventures. Since its inception in 2015, ShangBay Capital, under William's leadership, has emerged as a successful venture capital entity, nurturing 72 portfolio companies and achieving multiple successful exits. ShangBay's investment portfolio includes Ceribell, an AI-enabled EEG system that has become one of the best Medtech IPOs in recent years, and where ShangBay was the first institutional investor. Additionally, ShangBay has syndicated 26 portfolio companies with major strategics. Currently, William serves on the boards of directors for Luminopia, Aqua Medical, Meditrina, FemDx, and YorLabs. He has also previously served on the boards of NeuroVasc (acquired in 2019) and Arrinex (acquired by Stryker in 2019). As the Founding Managing Partner at ShangBay Capital, he has played a critical role in leading and executing investment transactions to drive business success.
With over two decades of experience in corporate finance, mergers and acquisitions, and capital markets across Asia and the U.S., William Dai brings a wealth of expertise to the healthcare investment realm. Prior to founding ShangBay Capital, he held CFO positions at ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE: NPD), Microport Scientific Corporation (HK: 00853), and Boston Scientific China, where he played pivotal roles in driving business transactions and fostering organizational success.
'This past year has underscored the profound impact that medical technology can have on improving patient outcomes. I feel privileged to contribute to this dynamic and meaningful field, working alongside innovators who are redefining what's possible in healthcare. As we look ahead, I remain committed to supporting the next generation of pioneering medtech companies,' remarked William Dai.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Public markets primed for US IPO revival despite tariff uncertainty, NYSE President Martin says
By Arasu Kannagi Basil (Reuters) -Intercontinental Exchange-owned NYSE's President Lynn Martin said on Thursday that public markets were ready for well-prepared companies despite tariff unease as easing volatility was setting the stage for a rebound in U.S. IPO activity. Optimism that 2025 would finally be the year for a strong rebound in U.S. IPO market activity has recently been tempered by tariff-driven uncertainty, but the window seems to be opening up again after volatility eased and equities bounced back. "There's been this narrative in the market, particularly for the last two years. It's a bit false that companies can't go public," Martin said at the Piper Sandler Global Exchange & Trading Conference. The companies debuting at this time were public-market ready, she said, highlighting the successful listings of cybersecurity firm Rubrik and social media platform Reddit last year. "They were ready to go. They went, and they've done extraordinarily well," Martin said. Analysts say the IPO market could be in the early stages of a broader pickup, but that sustained stability was needed before the window opens fully. "We expect approximately one or two deals per week in June, ramping up a bit in July after Independence Day, and if all goes well, a full rebound in September, October after the summer lull," said Matt Kennedy, senior strategist at Renaissance Capital, a provider of IPO-focused research and ETFs. NYSE TEXAS The impending launch of the Texas Stock Exchange, backed by Wall Street giants BlackRock and Citadel Securities, is set to heat up the competition in listings markets. The NYSE was following its playbook, talking to its customers about why more of them were moving to Texas, Martin said. NYSE Texas officially opened for business in March and has secured a handful of companies over the past few weeks - including Trump Media & Technology Group - as its "founding" members. "The conversations we're having are incredibly positive," Martin said, adding that NYSE Texas had another double-digit dual listing lined up. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Is this S&P 500 stock a once-in-a-decade passive income opportunity?
The S&P 500 has recovered from its volatile start to the year and is within touching distance of its record highs. At the same time, some quality shares are trading at exceptionally low prices. One example is Johnson & Johnson (NYSE:JNJ). As a rule, I stay away from pharmaceutical stocks, but I'm considering making a rare exception for this one. Johnson & Johnson has recently divested its consumer products business. The company now generates around 66% of its revenues from pharmaceuticals and 33% from medical devices. The main reason I generally stay away from stocks like this is I don't feel like I can evaluate them accurately. I'm not a medical professional and that means I can't confidently evaluate drug pipelines. That makes it hard to work out which businesses have the best prospects. And in fairness to me, it's not always straightforward even for people who do have specialist expertise in this sector. Johnson & Johnson does have some competitive strengths in this area – most notably its scale and its exceptional balance sheet. But there's something else that stands out to me about the company. A key part of what makes Johnson & Johnson unique is its culture. And this is set out in the 'Credo' – a document, which states that the company's priorities are, in order: Doctors, patients, nurses, and users of its products Employees Communities Shareholders In other words, focus on putting customers first and doing the right thing and the returns will follow. This ethical outlook is a key part of what has allowed the business to survive and thrive over decades. A lot of businesses have codes of conduct or ethical frameworks. But there's evidence that Johnson & Johnson's Credo means its culture is more entrenched than it is at other companies. The firm's reaction to the 1982 Tylenol crisis is now a well-known case study in ethical leadership. And it doesn't take specialist medical knowledge to appreciate the significance of this. Right now, shares in Johnson & Johnson come with a dividend yield of around 3.25%. That doesn't exactly jump out as a passive income opportunity, but it's the highest it has been in the last 10 years. This is a sign investors are unusually pessimistic about a stock they normally hold in high regard. And a key reason for this is the situation in the US at the moment. The situation is still developing, but potential risks include slower drug approval processes and price controls. Neither of these would be good for companies like Johnson & Johnson. The risk is real, but this might be the kind of opportunity that comes around once in a decade. Given the company's long-term strengths, I think it's worth taking seriously. I think Johnson & Johnson's biggest unique strength is its culture. Even if I'm wrong, there's clearly a lot to like about a company that has more than 50 years of consecutive dividend increases. Most of the time, the stock market appreciates the quality of the business. But it's unusually cheap at the moment and on that basis, it's certainly one to consider right now. The post Is this S&P 500 stock a once-in-a-decade passive income opportunity? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
1 Top REIT to Buy Hand Over Fist in June for Passive Income
VICI Properties currently pays a 5.5%-yielding dividend. It backs that high-yielding payout with stable cash flow and a solid financial profile. The REIT has plenty of room to continue expanding to support its growing dividend. 10 stocks we like better than Vici Properties › Investing in real estate can be a terrific way to make passive income. Tenants pay rent, which should cover all property expenses with room to spare, providing the landlord with income. One of the easiest ways to make passive income from real estate is to invest in a real estate investment trust (REIT). These companies own portfolios of income-generating real estate. They distribute a portion of that income to shareholders via dividend payments. VICI Properties (NYSE: VICI) is a top REIT to buy for passive income this June. It currently pays a 5.5%-yielding dividend -- more than four times the S&P 500's (SNPINDEX: ^GSPC) sub-1.5% yield -- that it has been growing at an above-average rate. That combination of yield and growth enables investors to collect lots of income now and even more in the future. VICI Properties is one of the largest REITs focused on experiential real estate. It owns market-leading gaming, hospitality, wellness, entertainment, and leisure destinations, like the Venetian Resort Las Vegas and the Chelsea Piers sports and entertainment complex in New York City. The REIT leases these properties to operating companies under very long-term triple net (NNN) leases (40-year average remaining lease term) that increasingly escalate rents at rates tied to inflation (42% this year, rising to 90% by 2035). Those leases, which require that tenants cover all property operating costs (including routine maintenance, real estate taxes, and building insurance), provide it with stable, steadily rising rental income. The REIT pays out about 75% of its adjusted funds from operations (FFO) in dividends each year. That gives it a big cushion while enabling it to retain a meaningful amount of its cash flow to fund new investments. VICI Properties also has a solid investment-grade-rated balance sheet, providing it with additional financial flexibility. Its net leverage ratio was 5.3 times at the end of the first quarter, right in the middle of its 5.0x-5.5x target range. The company's stable cash flow and solid financial profile put its high-yielding dividend on a very stable foundation. VICI Properties' rising rental income and growing real estate portfolio have supported its ability to increase its dividend. The REIT has raised its payment in all seven years since its formation. It has grown its dividend at a 7.4% compound annual rate, which is much faster than the 2.3% average pace of other REITs focused on investing in NNN real estate. VICI Properties already has a leading experiential real estate portfolio. The REIT owns 54 gaming properties, including 10 trophy assets on the Las Vegas Strip. The company also owns Chelsea Piers and 38 bowling entertainment centers leased to Lucky Strike. Despite its already extensive portfolio, VICI Properties has plenty of room to continue growing. There is an estimated $400 billion in U.S. gaming properties not currently owned by REITs or operated by tribal gaming companies. These properties alone represent a massive growth opportunity for the roughly $50 billion REIT (by enterprise value). Meanwhile, tribal casinos represent an additional investment opportunity. VICI Properties owns several casinos leased to tribal operators. It has also made two loan investments related to properties on tribal land, including its recent partnership with Red Rock Resorts to fund the development of the North Fork Mono Casino and Resort in California. On top of that, there's a large and growing opportunity to invest in nongaming experiential properties. VICI Properties has been getting in on the ground floor of this opportunity by forming financial partnerships with experiential property operators. It has made loans to Great Wolf Lodge (indoor water parks), Canyon Ranch (wellness retreats), Cabot (destination golf), and others. Many of these loans give the REIT the option to acquire properties from the developer in sale-leaseback transactions. VICI Properties is always on the lookout for new partners and experiential real estate investment opportunities. It formed a strategic relationship with Cain International and Eldridge Industries earlier this year to identify and pursue unique experiential real estate. The first investment is a $300 million mezzanine loan to support the development of One Beverly Hills, a landmark luxury mixed-use development featuring an all-suite Aman Hotel, high-end boutiques, world-class culinary destinations, and a botanical garden. The REIT's ability to continue expanding its portfolio supports its capacity to grow its dividend. VICI Properties pays an attractive, steadily rising dividend backed by a world-class experiential real estate portfolio. The REIT also has a rock-solid financial profile, enabling it to continue growing its portfolio and dividend. Its combination of a high-yield dividend and above-average growth profile makes it a top REIT to buy for income this June. Before you buy stock in Vici Properties, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vici Properties wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Matt DiLallo has positions in Vici Properties. The Motley Fool recommends Red Rock Resorts and Vici Properties. The Motley Fool has a disclosure policy. 1 Top REIT to Buy Hand Over Fist in June for Passive Income was originally published by The Motley Fool
